Skip to content

Corbus cystic fibrosis med shows positive preclinical data

February 25, 2017

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today that Michael Knowles, M.D., a member of the Company’s Scientific Advisory Board and Professor of Pulmonary and Critical Care Medicine, University of North Carolina Chapel Hill will present findings demonstrating positive effects of JBT-101 on reducing inflammatory mediators in alveolar macrophages isolated from excised lungs of cystic fibrosis (CF) patients. The presentation will be on March 13, 2017, in New York City, at the Research and Development Day hosted by Corbus.

Normally, alveolar macrophages play an important role in lung host defense, secreting inflammatory mediators in healthy subjects in response to microbial infection. However, such macrophages from CF patients exhibit an exaggerated and persistent state of hyper-inflammation that has long-term consequences of irreversible damage to the lung and contributes to the serious morbidity and decreased life-span associated with CF.

Dr. Knowles will present experimental preclinical data from human alveolar macrophages treated with JBT-101 that have been isolated from excised lungs of individuals with CF undergoing lung transplantation. To mimic infection, the patient’s macrophages were stimulated ex-vivo with lipopolysaccharide derived from P. aeruginosa, which is a major bacterial pathogen in CF, and cultured with and without JBT-101. Macrophages treated with JBT-101 demonstrated a reduced production of two important pro-inflammatory cytokines (tumor necrosis factor alpha and interleukin-6) compared to stimulated macrophages untreated by JBT-101. These pro-inflammatory mediators have been previously shown to be abnormally over-expressed by CF alveolar macrophages at both basal and LPS-stimulated conditions compared to macrophages from healthy donors.

“These results are encouraging with respect to the potential of JBT-101 to modify inflammation in the lungs of CF patients, which offers an entirely novel approach to treat all genotypes of this chronic life-shortening disease,” said Dr. Knowles.

“This human model has allowed us to explore the impact of JBT-101 on immune function of primary cells derived from CF patients’ lungs. The data demonstrate JBT-101’s unique mechanism of action that could help address chronic lung inflammation in CF patients potentially without the immunosuppression risk associated with existing anti-inflammatory therapies that render them inappropriate for usage in this disease,” stated Mark A. Tepper PhD, President and Chief Scientific Officer of Corbus. “We look forward to our upcoming Phase 2 clinical data of JBT-101 in CF patients for further insight into this potential benefit.”

Interested parties may access a live video webcast and accompanying slide presentation on the Events page of the Investors section of the Company’s website at The webcast will be accessible for 90 days following the event.


From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: